Back to search

Article

SARS-CoV-2 antibody responses in patients with aggressive haematological malignancies

2020-10-01

Abstract excerpt

The development of antibody responses to SARS-CoV-2 is an indicator of seroprevalence and may afford protection from infection. It has been presumed that antibody responses to SARS-CoV-2 will be impaired in patients with aggressive haematological malignancy (PHM) due to underlying immunological dysfunction caused by malignancy or systemic anti-cancer treatment (SACT), placing them at increased risk. Here we analys...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9ed8a3b6-4920-5065-8e33-9b0d7628b4b6
DOI
10.1101/2020.09.29.20202846
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
SARS-CoV-2 antibody responses in patients with aggressive haematological malignanciesDOI 10.1101/2020.09.29.20202846
Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE studySemantic proximity
Challenges in the Clinical Management of SARS-CoV2-Infected Patients with Haematological MalignanciesSemantic proximity
Antibody Responses to SARS-CoV-2 Infection in Cancer PatientsSemantic proximity
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE studySemantic proximity
SARS-CoV-2 specific memory B-cells from individuals with diverse disease severities recognize SARS-CoV-2 variants of concernSemantic proximity
Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trialSemantic proximity
Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccinationSemantic proximity
Incidence and Immunomic Features of Apyretic COVID-19 in Patients Affected by Solid Tumors: a Prospective Cohort Study.Semantic proximity
Performance, Dynamic Change and Clinical Relevance of SARS-CoV-2 Antibody ResponsesSemantic proximity
Durable tracking anti-SARS-CoV-2 antibodies of cancer patients recovered from COVID-19Semantic proximity
Immune responses following third COVID-19 vaccination are reduced in patients with hematologic malignancies compared to patients with solid cancerSemantic proximity
Scottish COVID Cancer Immunity Prevalence (SCCAMP) - a Longitudinal Study of Patients with Cancer Receiving Active Anti-Cancer Treatment During the COVID-19 PandemicSemantic proximity
Select a neighboring publication to make it the new centre.